

IMMUNOGEN INC
Form 8-K
February 12, 2003

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): FEBRUARY 12, 2003

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

Massachusetts
(State or other
jurisdiction of
incorporation)

0-17999
(Commission
File Number)

04-2726691
(IRS Employer
Identification No.)

128 Sidney Street, Cambridge, MA 02139

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(617) 995-2500**

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

(c) Exhibits

Exhibit No.	Exhibit
99.1	Certification of Chief Executive Officer and Chief Financial Officer

ITEM 9. REGULATION FD DISCLOSURE

In connection with the Quarterly Report on Form 10-Q of ImmunoGen, Inc. (the Company) for the quarterly period ended December 31, 2002, as filed with the Securities and Exchange Commission concurrently herewith, the Company hereby files the written statement required by Section 906 of the Sarbanes-Oxley Act of 2002. On February 12, 2003, Mitchel Sayare, Chief Executive Officer and President of the Company and Gregg D. Beloff, Chief Financial Officer and Vice President, Finance of the Company, each executed this written statement. A copy of the foregoing written statement is attached hereto as an exhibit and incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ImmunoGen, Inc.
(Registrant)

Date: FEBRUARY 12, 2003

/s/ Gregg D. Beloff
Gregg D. Beloff
Chief Financial Officer and
Vice President, Finance

EXHIBIT INDEX

Exhibit No.	Exhibit
99.1	Certification of Chief Executive Officer and Chief Financial Officer